AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

OCALA, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the first subject has been dosed at Erasmus Medical Center ("Erasmus MC") in a Phase 1b/2 clinical trial combining AIM's Ampligen® (rintatolimod) with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for the treatment of late-stage pancreatic cancer (the "DURIPANC Study"). The DURIPANC Study is an investigator-initiated, exploratory, open-label, single-center study ...